Aspirin intolerance. III. Subtypes, familial occurence, and cross-reactivity with tartarazine.
Evidence has been presented supporting the hypothesis that at least 2 different types of mechanisms may be involved in aspirin intolerance, one resulting in bronchospasm and the other producing urticaria/angioedema. Bronchospasm is the predominant symptom of aspirin intolerance in patients who have asthma. In contrast, the predominant symptom of aspirin intolerance in patients who have rhinitis is urticaria/angioedema. In the bronchospastic type of aspirin intolerance, there is a significant correlation with an increased frequency of nasal polyposis, and with a similar ageonset of asthma and aspirin intolerance. These correlations were not present in the urticari/angioedema type. Additional evidence for familial occurrence of aspirin intolerance is presented, and its relationship with subtypes of aaspirin intolerance is discussed. In a double-blind, crossover study with normal control subjects matched by age and sex 15% (6/40) of aspirin-intolerant individuals had significant adverse reactions to tartrazine challenge and not to the placebo. None of the 40 normal control subjects had any adverse reactions.
D000799:Angioedema / Q000150:complications; D001241:Aspirin / Q000276:immunology*; D001249:Asthma / Q000209:etiology; D001391:Azo Compounds / Q000276:immunology*; D001557:Benzenesulfonates / Q000276:immunology*; D001986:Bronchial Spasm / Q000150:complications; D003429:Cross Reactions; D004342:Drug Hypersensitivity / Q000235:genetics / Q000276:immunology; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D010366:Peak Expiratory Flow Rate; D010375:Pedigree; D012129:Respiratory Function Tests; D006255:Rhinitis, Allergic, Seasonal / Q000209:etiology; D014109:Total Lung Capacity; D014581:Urticaria / Q000150:complications; D014797:Vital Capacity
D001391:Azo Compounds; D001557:Benzenesulfonates; D001241:Aspirin